PMID- 34940336
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211226
IS  - 2310-2861 (Electronic)
IS  - 2310-2861 (Linking)
VI  - 7
IP  - 4
DP  - 2021 Dec 20
TI  - Development, Optimization, and In Vitro Evaluation of Novel Oral Long-Acting 
      Resveratrol Nanocomposite In-Situ Gelling Film in the Treatment of Colorectal 
      Cancer.
LID - 10.3390/gels7040276 [doi]
LID - 276
AB  - This study aimed to develop and evaluate sustained-release (SR) long-acting oral 
      nanocomposites in-situ gelling films of resveratrol (Rv) to treat colorectal 
      cancer. In these formulations, Rv-Soy protein (Rv-Sp) wet granules were prepared 
      by the kneading method and then encapsulated in the sodium alginate (NA) dry 
      films. The prepared nanocomposite in-situ gels films were characterized using 
      dynamic light scattering, Fourier-transform infrared spectroscopy, X-ray 
      diffraction, and scanning electron microscopy. The optimized formulations were 
      further evaluated based on drug encapsulation efficiency, pH-drug release 
      profile, swelling study, and storage time effects. The optimized formulation was 
      tested for its anticancer activity against colorectal cancer cells using the 
      cytotoxicity assessment, apoptosis testing, cell cycle analysis, gene expression 
      analysis, and protein estimation by the reverse-transcriptase polymerase chain 
      reaction and enzyme-linked immunosorbent assay methods, respectively. The optimum 
      film showed encapsulation efficiency of 97.87% +/- 0.51 and drug release of 14.45% 
      +/- 0.043 after 8 h. All physiochemical characterizations confirmed, reasoned, and 
      supported the drug release experiment's findings and the encapsulation assay. The 
      Rv nanocomposite formulation showed concentration-dependent cytotoxicity enhanced 
      apoptotic activity as compared to free Rv (p < 0.05). In addition, Rv 
      nanocomposite formulation caused a significant increase in Bcl-2-associated 
      protein X (Bax) and a decrease in expression of B-cell lymphoma 2, interleukin 1 
      beta, IL-6, and tumor necrosis factor-alpha (Bcl2, IL-1beta, IL-6, and TNF-alpha 
      respectively) compared to that of free Rv in HCT-116 cells. These results suggest 
      that long-acting Rv nanocomposite gels could be a promising agent for colorectal 
      cancer treatment.
FAU - Md, Shadab
AU  - Md S
AUID- ORCID: 0000-0002-9343-1066
AD  - Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, 
      Jeddah 21589, Saudi Arabia.
AD  - Center of Excellence for Drug Research & Pharmaceutical Industries, King 
      Abdulaziz University, Jeddah 21589, Saudi Arabia.
AD  - Mohamed Saeed Tamer Chair for Pharmaceutical Industries, King Abdulaziz 
      University, Jeddah 21589, Saudi Arabia.
FAU - Abdullah, Samaa
AU  - Abdullah S
AUID- ORCID: 0000-0001-5245-6489
AD  - Department of Biological Sciences, Faculty of Science, King Abdulaziz University, 
      Jeddah 21589, Saudi Arabia.
FAU - Alhakamy, Nabil A
AU  - Alhakamy NA
AUID- ORCID: 0000-0002-3826-1519
AD  - Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, 
      Jeddah 21589, Saudi Arabia.
AD  - Center of Excellence for Drug Research & Pharmaceutical Industries, King 
      Abdulaziz University, Jeddah 21589, Saudi Arabia.
AD  - Mohamed Saeed Tamer Chair for Pharmaceutical Industries, King Abdulaziz 
      University, Jeddah 21589, Saudi Arabia.
FAU - Alharbi, Waleed S
AU  - Alharbi WS
AUID- ORCID: 0000-0001-7727-6126
AD  - Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, 
      Jeddah 21589, Saudi Arabia.
AD  - Center of Excellence for Drug Research & Pharmaceutical Industries, King 
      Abdulaziz University, Jeddah 21589, Saudi Arabia.
FAU - Ahmad, Javed
AU  - Ahmad J
AUID- ORCID: 0000-0002-7025-751X
AD  - Department of Pharmaceutics, College of Pharmacy, Najran University, Najran 
      11001, Saudi Arabia.
FAU - Shaik, Rasheed A
AU  - Shaik RA
AUID- ORCID: 0000-0001-7959-8647
AD  - Department of Pharmacology & Toxicology, Faculty of Pharmacy, King Abdulaziz 
      University, Jeddah 21589, Saudi Arabia.
FAU - Ansari, Mohammad Javed
AU  - Ansari MJ
AUID- ORCID: 0000-0001-9266-7133
AD  - Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz 
      University, Al-Kharj 11942, Saudi Arabia.
FAU - Ibrahim, Ibrahim M
AU  - Ibrahim IM
AUID- ORCID: 0000-0001-5280-9555
AD  - Department of Pharmacology, Faculty of Medicine, King Abdulaziz University, 
      Jeddah 21589, Saudi Arabia.
FAU - Ali, Javed
AU  - Ali J
AUID- ORCID: 0000-0001-5308-0655
AD  - Department of Pharmaceutics, School of Pharmaceutical Education and Research, 
      Jamia Hamdard, New Delhi 110062, India.
LA  - eng
GR  - IFPRC-151-166-2020/Deputyship for Research & Innovation, Ministry of Education in 
      Saudi Arabia and King Abdulaziz University/
PT  - Journal Article
DEP - 20211220
PL  - Switzerland
TA  - Gels
JT  - Gels (Basel, Switzerland)
JID - 101696925
PMC - PMC8702129
OTO - NOTNLM
OT  - alginate film
OT  - colorectal cancer
OT  - in-situ gel
OT  - nanocomposites
OT  - oral sustained-release film
OT  - resveratrol
OT  - soy protein
COIS- The authors report no declarations of interest. This work was filed in the USPTO 
      under U.S. serial number 17/175764.
EDAT- 2021/12/24 06:00
MHDA- 2021/12/24 06:01
PMCR- 2021/12/20
CRDT- 2021/12/23 12:43
PHST- 2021/12/04 00:00 [received]
PHST- 2021/12/14 00:00 [revised]
PHST- 2021/12/16 00:00 [accepted]
PHST- 2021/12/23 12:43 [entrez]
PHST- 2021/12/24 06:00 [pubmed]
PHST- 2021/12/24 06:01 [medline]
PHST- 2021/12/20 00:00 [pmc-release]
AID - gels7040276 [pii]
AID - gels-07-00276 [pii]
AID - 10.3390/gels7040276 [doi]
PST - epublish
SO  - Gels. 2021 Dec 20;7(4):276. doi: 10.3390/gels7040276.